Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Corporate Update (January 2022)
16 slides from Oncotelic Therapeutics's corporate update, Jan 28, 2022
Slide 1: Oncotelic Therapeutics: A TGF-beta Company
ONCOTELIC THERAPEUTICS A TGF-beta Company Anthony E. Maida,tH, Ph.D., MA, MBA, BA, BA Chief Clinical Officer - Translational Medicine Oncotelic Therapeutics, Inc. 01/26/22 WWW.ONCOTELIC.COM
Slide 2: Management Team
Management Team * Vuong Trieu, PhD (CEO). Dr. Trieu, an expert in pharmaceutical development, currently serves as CEO/Chairman of Oncotelic Inc.. Previously he was President and CEO of Igdrasol- developer of 2nd generation Abraxane- Cynviloq. Igdrasol merged with Sorrento Therapeutics, he became CSO
Slide 3: Pipeline (Oncology and Virology)
ONCOTELIC THERAPEUTICS OT-101 +1L-2/ V Solid Tumors OT-101 DIPG i Pancreatic OT-101+Abx Cancer, OT-101+ TMZ Glioblastoma Pediatric Melanoma Phase 1 ABio/ Clinigen RPD/Approval on Ph2 Lung Cancer/ Merck Post Infection Damages RPD/ Approval on Ph2 RPD/ Approval on Ph2 Phase 2 Pipeline (Oncology and Vi
Slide 4: OT-101 / Trabedersen
ONCOTELIC THERAPEUTICS OT-101/ Trabedersen WWW.ONCOTELIC.COM 4
Slide 5: A Brief Review of TGF-B2
A Brief Review of TGF-B2 ¢ A pleiotropic and promiscuous immune modulator * One of three (3) isomers, TGF-B1, TGF-B2 , TGF-B3 * Ahomodimeric cytokine 25kD that modulates, cell growth, differentiations, a potent immune suppressor, may act as a tumor promoter or tumor suppressor, induce EMT (epithelia
Slide 6: Antisense as Next Generation Drugs
Antisense as Next Generation Drugs Inception Size Drug Discovery Success Rate Predictable PK On Target Safety Off Target Safety Risk Profile Speed of Development Manufacturing Cost Amenable to Individual Therapy ONCOTELIC THERAPEUTICS 1850s to present 200-500 Random screening Low-~5% No Target Speci
Slide 7: OT-101: Drug Product- TGF-B2 Antisense
OT-101: Drug Product- TGF-B2 Antisense. Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-B2 messenger RNA * Ready for registration trials--Over 200 patients treated across 6 clinical trials * Strong Patent protection until 203
Slide 8: Clinical Efficacy: Glioblastoma
Clinical Efficacy: Glioblastoma Treatment failure patients (recalcitrant to radiation, surgery, and chemo) Objective responses were observed among the 87 evaluable patients treated with OT-101: ¢ Best Objective Responses were: 5 CR (5.9%), 14 PR (16.5%), 28 SD (31.8%), and 40 PD (45.9%) * Confirmed
Slide 9: Clinical Efficacy: Pancreatic Cancer
Clinical Efficacy: Pancreatic Cancer Phase 2- treatment failure pts/ recalcitrant to Whipple and chemo * Patient 1006: CR as far out as 77 mos * Patient 1022: OS of 40 months * Surgery: Whipple's procedure * Surgery: Whipple's procedure * 15 line: 5-FU/LV, Dose 425 mg/m2 * 1% line: Radiation therapy
Slide 10: Clinical Efficacy: COVID
Clinical Efficacy: COVID + Large surge in TGF-beta during active COVID infection ¢ Anestablished role of TGF-beta in scarring and late stage post-COVID symptoms ¢ Strong in vitro activity against SARS-COV-2 on Vero cells * OT-101 is in phase 2 clinical trial against COVID @. 150000: § 100000. = = 50
Slide 11: Double-Blind Randomized Study of OT-101 in Hospitalized COVID-19 Subjects
A Double-Blind, Randomized, Placebo-Controlled, Multi- Center Study of OT-101 in Hospitalized COVID-19 Subjects * Conducted in Peru and Argentina - 6 sites 3 in Peru and 3 in Argentina * 20 Part 1 Patients and 12 Part 2 Patients, 2:1 Randomization * Day 7 Mortality Rate of 4.5% vs 20% for Placebo fo
Slide 12: Future Plans
Future Plans ¢ Phase II Clinical Trial in Metastatic Pleural Mesothelioma (MPM), a combination of OT- 101 with a checkpoint inhibitor ¢ Phase Il Clinical Trial in NSCLC, combination study ¢ Phase II Clinical Trial in a Basket Study, high grade gliomas (HGG), Tumors of the midline brain and diffuse i
Slide 13: Rationale for Immunotherapy Combination
Rationale for Immunotherapy Combination * Data supportive of improved OS with higher innate immune reservoir -> supplement with boost to innate immune reservoir (Cytokine -> IL2, Cell supplement -> NK or CART or ADCC * Patients exhibited variable dynamics in IL-8 levels whereby increases were observ
Slide 14: OT-101 Biomarker Program
OT-101 Biomarker Program * This is a combination of mesothelioma, lung, pancreatic, melanoma, DIPG, and GPM clinical trials in collaboration with Merck combining Keytruda with OT-101. * Tumor biopsy previous to treatment and post treatment will be used to generate predictive biomarkers for tumor res
Slide 15: Sequence of events
Sequence of events Mm |llumina Panel for blood biomarker NanoString nCounter® meg assays (I/O and Fibrosis Panels) — Spatial IHC Transcriptome Analysis jaa — Deep sequencing Positive clinical outcome Positive finding on blood and Nanostring Panel ONCOTELIC THERAPEUTICS ig
Slide 16: High TGF-B signature predicts immunotherapy resistance in gynecologic cancer patients
Ni, Y., Soliman, A., Joehlin-Price, A. et al. High TGF-B signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition. Precis. Onc. 5, 1 A a ME ET Diseasesite CARER Bs i | | BCARS 1 r PULP Wi) Bere an fal ay et Be oe re re THERAPEUTICS (2021).
Oncotelic Therapeutics — Corporate Update (January 2022) on 6ix